Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 10/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 4/20 | 0.34 |
| ▸ | EGFR | P00533 | 4/20 | 0.34 |
| ▸ | SRC | P12931 | 4/20 | 0.34 |
| ▸ | ABL2 | P42684 | 4/20 | 0.34 |
| ▸ | LCK | P06239 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5091123 | 1.00 | CALCRL (0.38) | CALCRLDRD2DRD4DRD3RAMP1 | |
| SCHEMBL5091185 | 0.91 | DRD2 (0.46) | CALCRLDRD2DRD4DRD3RAMP1 | |
| SCHEMBL5091183 | 0.91 | DRD2 (0.46) | CALCRLDRD2DRD4DRD3RAMP1 | |
| SCHEMBL5088970 | 0.91 | DRD2 (0.39) | CALCRLDRD2DRD4DRD3RAMP1 | |
| SCHEMBL5088963 | 0.91 | DRD2 (0.39) | CALCRLDRD2DRD4DRD3RAMP1 | |
| SCHEMBL5091154 | 0.90 | CALCRL (0.43) | CALCRLDRD2DRD4DRD3RAMP1 | |
| SCHEMBL5091156 | 0.90 | CALCRL (0.43) | CALCRLDRD2DRD4DRD3RAMP1 | |
| SCHEMBL5098336 | 0.89 | HSD11B1 (0.38) | CALCRLDRD2DRD4DRD3RAMP1 | |
| SCHEMBL5098339 | 0.89 | HSD11B1 (0.38) | CALCRLDRD2DRD4DRD3RAMP1 | |
| SCHEMBL5093923 | 0.88 | CALCRL (0.36) | CALCRLDRD2DRD4DRD3RAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407963-B2 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-08-05 | — | — | US | claimed |
| EP-1228059-B1 | NOVEL CYCLOPROPANES AS CGRP ANTAGONISTS, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-03 | — | — | EP | claimed |
| US-20030139417-A1 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-24 | — | — | US | claimed |
| US-7407963-B2 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-08-05 | — | — | US | disclosed |
| US-20050267137-A1 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-12-01 | — | — | US | disclosed |
| EP-1228059-B1 | NOVEL CYCLOPROPANES AS CGRP ANTAGONISTS, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20030139417-A1 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267137-A1 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | CALCRL, CALCA, CALCR | CALCRL 1/4885DRD2 655/4885DRD4 1035/4885 |
| US-20030139417-A1 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | CALCA, CALCRL, CALCB | CALCRL 2/4885DRD2 640/4885DRD4 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.